Press Releases

Let's spread the word about Immunotherapy! Click to share this page with your community.
March 30, 2021

CRI and RevImmune Announce Dosing of First Patient in New Phase 2 Study

First study to test RevImmune’s IL-7 drug candidate in cancer patients infected with the SARS-CoV-2 coronavirus at increased risk of progressing to severe stages of COVID-19

November 11, 2020

Combination Drug Strategies Gain Ground in PD-1/PD-L1 Pipeline

Combination drug strategies gain ground in global immuno-oncology pipeline of PD-1 and PD-L1 clinical trials, new report from Cancer Research Institute reveals.

November 11, 2020

Jill O’Donnell-Tormey Receives Inaugural Tara Withington Public Service Award

Cancer Research Institute CEO and Director of Scientific Affairs Dr. Jill O’Donnell-Tormey receives inaugural Tara Withington Public Service Award from the Society for Immunotherapy of Cancer.

October 09, 2020

TESLA Initiative Discovers Keys That Could Unlock Better Personalized Treatments to Destroy Cancer

International neoantigen initiative Tumor Neoantigen Selection Alliance (TESLA) identifies parameters for cancer vaccine or cell therapy advancement

September 18, 2020

IO Pipeline Continues Significant Growth

Immunotherapy drug development pipeline continues significant growth in 2020 despite global pandemic impact.

*Immunotherapy results may vary from patient to patient.